drugset / Trial / NCT02799030
A Clinical Trial of Topical Photodynamic Therapy With 5-aminolevulinic Acid for the Treatment of Actinic Keratosis
RandomizedParallel-groupTriple-blindTreatment
Summary
This was a placebo controlled, double blind, randomized phase II dose-response study to evaluate the efficacy and safety of BF-200 ALA (containing the active ingredient 5 - aminolevulinic acid- ALA) used with photodynamic therapy (PDT) in patients with actinic keratosis (AK).
Timeline
- Start
- 2006-10
- Primary completion
- 2007-03
- Completion
- 2007-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aminolevulinic Acid | Diagnostic / imaging agent | 1 % | Topical |
| Subject | Aminolevulinic Acid | Diagnostic / imaging agent | 3 % | Topical |
| Subject | Aminolevulinic Acid | Diagnostic / imaging agent | 10 % | Topical |